Trials / Recruiting
RecruitingNCT06852378
Iliopsoas Nerve Block and Femoral Nerve Block in Hip Fracture Surgeries
Comparison Between Iliopsoas Nerve Block and Femoral Nerve Block in Hip Fracture Surgeries
- Status
- Recruiting
- Phase
- —
- Study type
- Observational
- Enrollment
- 80 (estimated)
- Sponsor
- Ain Shams University · Academic / Other
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
This study aims to compare iliopsoas nerve Block (IPB) to femoral nerve block (FNB) regarding pain control, patient satisfaction, and early ambulation in patients undergoing hip fracture surgeries
Detailed description
Hip fractures are among the most frequent fractures seen in the emergency department and orthopedic trauma teams. The terms hip fracture and neck of femur fracture are used synonymously. Both terms describe a proximal femur fracture between the femoral head and 5 cm distal to the lesser trochanter. Iliopsoas nerve Block (IPB) is a promising motor-sparing analgesic technique that selectively targets the sensory branches of the hip joint originating from the femoral nerve and accessory obturator nerve, sparing the motor supply of quadriceps muscles. A femoral nerve block (FNB) is a simple nerve block that can be performed easily without or under ultrasound guidance. Under ultrasound guidance, the femoral artery and femoral nerve were identified clearly, and a needle was inserted using an in-plane approach from the lateral to the medial direction. Once the needle tip's position was confirmed, 10 ml of 0.5% bupivacaine was injected adjacent to the femoral nerve.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Iliopsoas nerve block | Patients will receive an Iliopsoas nerve block using 10 ml of bupivacaine 0.5%. |
| DRUG | Femoral nerve block | Patients will receive femoral nerve block using 10 ml of bupivacaine 0.5%. |
Timeline
- Start date
- 2025-03-01
- Primary completion
- 2026-02-01
- Completion
- 2026-02-01
- First posted
- 2025-02-28
- Last updated
- 2025-03-04
Locations
1 site across 1 country: Egypt
Source: ClinicalTrials.gov record NCT06852378. Inclusion in this directory is not an endorsement.